Amytrx Therapeutics is a biopharmaceutical company that advances the next generation of new anti-inflammatory peptide therapies.
Amytrx Therapeutics has raised $18.0M in total funding. The most recent round was Series A. The last funding was announced in May 2022.
Amytrx Therapeutics is headquartered in Nashville, United States.
Amytrx Therapeutics is a biopharmaceutical company that advances the next generation of new anti-inflammatory peptide therapies.
Amytrx Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amytrx Therapeutics — Funding & Investors." VCBacked, May 25, 2022, https://www.vcbacked.co/company/amytrx-therapeutics. Accessed August 14, 2026.
VCBacked. (2022). Amytrx Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/amytrx-therapeutics
{{cite web |title=Amytrx Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/amytrx-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated